Show simple item record

dc.contributor.authorRodriguez‑Mora, Sara 
dc.contributor.authorDe Wit, Flore
dc.contributor.authorGarcia-Perez, Javier 
dc.contributor.authorBermejo, Mercedes 
dc.contributor.authorLopez-Huertas, Maria Rosa 
dc.contributor.authorMateos, Elena 
dc.contributor.authorMarti, Pilar
dc.contributor.authorRocha, Susana 
dc.contributor.authorVigon-Hernandez, Lorena 
dc.contributor.authorChrist, Frauke
dc.contributor.authorDebyser, Zeger
dc.contributor.authorVílchez, Juan Jesús
dc.contributor.authorCoiras, Mayte 
dc.contributor.authorAlcamí, José 
dc.date.accessioned2019-10-07T08:06:59Z
dc.date.available2019-10-07T08:06:59Z
dc.date.issued2019-08
dc.identifier.citationPLoS Pathog. 2019 Aug 29;15(8):e1007958es_ES
dc.identifier.issn1553-7374es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8481
dc.description.abstractThe causative mutation responsible for limb girdle muscular dystrophy 1F (LGMD1F) is one heterozygous single nucleotide deletion in the stop codon of the nuclear import factor Transportin 3 gene (TNPO3). This mutation causes a carboxy-terminal extension of 15 amino acids, producing a protein of unknown function (TNPO3_mut) that is co-expressed with wild-type TNPO3 (TNPO3_wt). TNPO3 has been involved in the nuclear transport of serine/arginine-rich proteins such as splicing factors and also in HIV-1 infection through interaction with the viral integrase and capsid. We analyzed the effect of TNPO3_mut on HIV-1 infection using PBMCs from patients with LGMD1F infected ex vivo. HIV-1 infection was drastically impaired in these cells and viral integration was reduced 16-fold. No significant effects on viral reverse transcription and episomal 2-LTR circles were observed suggesting that the integration of HIV-1 genome was restricted. This is the second genetic defect described after CCR5Δ32 that shows strong resistance against HIV-1 infection.es_ES
dc.description.sponsorshipThis work was supported by crowfunding site PRECIPITA from FECYT, the MERCKSALUD Foundation, the Spanish Ministry of Science (FIS PI12/00969; PI16CIII/00034; SAF2016-78480-R); the Spanish AIDS Research Network RD16CIII/0002/0001 that is included in Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2016-2020, Instituto de Salud Carlos III, European Region Development Fund (FEDER); CIBERer-ISCIII (FIS PI16/00316) co-financed by the European Regional Development Founds (FEDER), IIS La Fe (2016-0388; 2018-0200), and Fundación Isabel Gemio (http://www.fundacionisabelgemio.com). The work of Dra. Sara Rodríguez-Mora is supported by the Asociación Conquistando Escalones, funded by Spanish LGMD1F patients and Sara Borrell grant from Instituto de Salud Carlos III. The work of Dra. María Rosa López-Huertas is financed by ISCIII-Subdirección General de Evaluación and European Funding for Regional Development (FEDER) and by Spanish Ministry of Economy and Competitiveness (PIE13/00040). The work of Elena Mateos is supported by the Spanish Ministry of Economy and Competitiveness SAF2016-78480-R. The work of Lorena Vigón is supported by a pre-doctoral grant from Instituto de Salud Carlos III. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPloses_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleThe mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infectiones_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID31465518es_ES
dc.format.volume15es_ES
dc.format.number8es_ES
dc.format.pagee1007958es_ES
dc.identifier.doi10.1371/journal.ppat.1007958es_ES
dc.contributor.funderFundación Española para la Ciencia y la Tecnologíaes_ES
dc.contributor.funderMERCKSALUD Foundationes_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)es_ES
dc.contributor.funderRedes Tematicas de Investigacion Cooperativa en Salud (España)es_ES
dc.contributor.funderFondo de Investigaciones Sanitariases_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderEuropean Funding for Regional Development (FEDER)es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1553-7374es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.ppat.1007958es_ES
dc.identifier.journalPLOS Pathogenses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12/00969es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16CIII/00034es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2016-78480-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0001es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/00316es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE13/00040es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional